Pingfu Fu

List of Publications by Year
in descending order

244 papers	8,857 citations	41258 49 h-index	54797 84 g-index
248 all docs	248 docs citations	248 times ranked	12871 citing authors

#	Article	IF	Citations
1	Adherence to Surgical Care Improvement Project Measures and the Association With Postoperative Infections. JAMA - Journal of the American Medical Association, 2010, 303, 2479.	3.8	487
2	Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. International Journal of Cancer, 2007, 121, 1424-1432.	2.3	304
3	Augmentation of umbilical cord blood (UCB) transplantation with ex vivoâ€"expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood, 2003, 101, 5061-5067.	0.6	291
4	Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery, 2010, 148, 1147-1153.	1.0	234
5	Nuclear Factor-Î°B/p65 (Rel A) Is Constitutively Activated in Human Prostate Adenocarcinoma and Correlates with Disease Progression. Neoplasia, 2004, 6, 390-400.	2.3	209
6	Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Nonâ€"Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 108-119.	1.6	187
7	Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid. Thyroid, 2013, 23, 600-604.	2.4	182
8	A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome. Thyroid, 2009, 19, 233-240.	2.4	174
9	Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model. Cancer Research, 2004, 64, 3334-3343.	0.4	169
10	Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 1526-1534.	3.2	168
11	Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study. Molecular Carcinogenesis, 2012, 51, 952-962.	1.3	167
12	Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis, 2014, 35, 452-460.	1.3	149
13	The Influence of Chronic Inflammation in Prostatic Carcinogenesis: A 5-Year Followup Study. Journal of Urology, 2006, 176, 1012-1016.	0.2	143
14	Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. Journal of the American Academy of Dermatology, 2011, 65, 576-583.	0.6	135
15	Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. American Journal of Kidney Diseases, 2000, 35, 257-265.	2.1	125
16	Kangaroo Care modifies preterm infant heart rate variability in response to heel stick pain: Pilot study. Early Human Development, 2009, 85, 561-567.	0.8	125
17	Circulating CD4[+] and CD8[+] T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology, 2013, 140, 87-97.	2.0	124
18	Differential Expression of S100A2 and S100A4 During Progression of Human Prostate Adenocarcinoma. Journal of Clinical Oncology, 2003, 21, 106-112.	0.8	120

#	Article	IF	Citations
19	Blockade of Î²-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice. Cancer Research, 2007, 67, 6925-6935.	0.4	117
20	Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults. British Journal of Haematology, 2004, 124, 488-498.	1.2	116
21	Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget, 2017, 8, 73745-73756.	0.8	114
22	Impairment of Regulatory T-Cell Function in Autoimmune Thyroid Disease. Thyroid, 2013, 23, 871-878.	2.4	110
23	Expansion of LTC‐ICs and Maintenance of p21 and BCL‐2 Expression in Cord Blood CD34+/CD38−Early Progenitors Cultured over Human MSCs as a Feeder Layer. Stem Cells, 2002, 20, 573-582.	1.4	108
24	Silicon phthalocyanine (pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers in Surgery and Medicine, 2010, 42, 888-895.	1.1	104
25	Genetic vs Environmental Factors That Correlate With Rosacea. JAMA Dermatology, 2015, 151, 1213.	2.0	102
26	Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology, 2008, 26, 570-576.	0.8	101
27	A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers. Clinical Cancer Research, 2009, 15, 3583-3590.	3.2	92
28	Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70â€"Bax interaction in prostate cancer. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 883-894.	2.2	90
29	Suppression of NF-Î²B and NF-Î²B-Regulated Gene Expression by Apigenin through IÎºBÎ± and IKK Pathway in TRAMP Mice. PLoS ONE, 2015, 10, e0138710.	1.1	86
30	Genetic Abnormalities of the <i>EGFR</i> Pathway in African American Patients With Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5620-5626.	0.8	85
31	Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images. Scientific Reports, 2017, 7, 13543.	1.6	85
32	CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction. The Lancet Digital Health, 2020, 2, e116-e128.	5.9	85
33	Upâ€regulation of insulinâ€like growth factor binding proteinâ€3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB Journal, 2005, 19, 2042-2044.	0.2	83
34	Apigenin blocks IKKÎ± activation and suppresses prostate cancer progression. Oncotarget, 2015, 6, 31216-31232.	0.8	78
35	Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma. Radiology: Artificial Intelligence, 2019, 1, 180012.	3.0	73
36	Direct Comparison of Umbilical Cord Blood versus Bone Marrowâ€"Derived Endothelial Precursor Cells in Mediating Neovascularization in Response to Vascular Ischemia. Biology of Blood and Marrow Transplantation, 2006, 12, 585-593.	2.0	72

#	Article	IF	Citations
37	MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents. Cancer Research, 2011, 71, 4494-4505.	0.4	72
38	Protection against oxidative DNA damage and stress in human prostate by glutathione <i>S</i>‑transferase P1. Molecular Carcinogenesis, 2014, 53, 8-18.	1.3	70
39	Phase II Trial of Radiosurgery to Magnetic Resonance Spectroscopy–Defined High-Risk Tumor Volumes in Patients With Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2012, 84, 668-674.	0.4	65
40	Combined SCLC Clinical and Pathologic Characteristics. Clinical Lung Cancer, 2013, 14, 113-119.	1.1	64
41	MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Human Pathology, 2013, 44, 2159-2166.	1.1	63
42	Progressive Proximal-to-Distal Reduction in Expression of the Tight Junction Complex in Colonic Epithelium of Virally-Suppressed HIV+ Individuals. PLoS Pathogens, 2014, 10, e1004198.	2.1	61
43	Phase II Study of Dasatinib (BMS‑354825) in Patients With Metastatic Adenocarcinoma of the Pancreas. Oncologist, 2013, 18, 1091-1092.	1.9	60
44	Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 2288-2302.	1.9	60
45	Deregulation of FOXO3A during prostate cancer progression. International Journal of Oncology, 2009, 34, 1613-20.	1.4	55
46	Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplantation, 2012, 47, 924-933.	1.3	55
47	An integrated nomogram combining deep learning, Prostate Imaging–Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study. The Lancet Digital Health, 2021, 3, e445-e454.	5.9	55
48	RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. Oncotarget, 2017, 8, 5992-6002.	0.8	55
49	Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer, 2019, 135, 1-9.	0.9	51
50	Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer, 2007, 55, 349-355.	0.9	50
51	Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin. Clinical Cancer Research, 2007, 13, 5862-5868.	3.2	49
52	Five-year survival does not equal cure in non–small cell lung cancer: A Surveillance, Epidemiology, and End Results–based analysis of variables affecting 10- to 18-year survival. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1307-1313.	0.4	48
53	Factors That Affect Skin Aging. Archives of Dermatology, 2009, 145, 1375-9.	1.7	47
54	Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review. Pituitary, 2014, 17, 575-587.	1.6	47

#	Article	IF	Citations
55	Upregulation of SATB1 Is Associated with Prostate Cancer Aggressiveness and Disease Progression. PLoS ONE, 2013, 8, e53527.	1.1	46
56	Apigenin Attenuates Insulin-Like Growth Factor-I Signaling in an Autochthonous Mouse Prostate Cancer Model. Pharmaceutical Research, 2012, 29, 1506-1517.	1.7	45
57	Green tea–induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase–3 suppresses prostate cancer progression through histone–modifying enzymes. Molecular Carcinogenesis, 2019, 58, 1194-1207.	1.3	45
58	Dose-Modified Oral Chemotherapy in the Treatment of AIDS-Related Non-Hodgkin's Lymphoma in East Africa. Journal of Clinical Oncology, 2009, 27, 3480-3488.	0.8	44
59	Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings. PLoS ONE, 2018, 13, e0200730.	1.1	44
60	Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head and Neck, 2015, 37, 1665-1671.	0.9	43
61	Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts. Biology of Blood and Marrow Transplantation, 2011, 17, 970-978.	2.0	42
62	Uracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed. Molecular Cancer Therapeutics, 2013, 12, 2248-2260.	1.9	42
63	Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. Cancer Medicine, 2019, 8, 1459-1466.	1.3	42
64	Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis. Cancer Research, 2022, 82, 334-345.	0.4	42
65	A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery, 2002, 132, 589-604.	1.0	41
66	15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3β and a Tumor Suppressor in Lung Cancer. Cancer Research, 2008, 68, 5040-5048.	0.4	40
67	Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 57, 362-370.	0.4	39
68	Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival. Clinical Cancer Research, 2014, 20, 5124-5132.	3.2	39
69	Ten-Year Outcomes: The Clinical Utility of Single Photon Emission Computed Tomography/Computed Tomography Capromab Pendetide (Prostascint) in a Cohort Diagnosed With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 29-34.	0.4	38
70	A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study. The Lancet Digital Health, 2020, 2, e594-e606.	5.9	38
71	Oxidative Stress and Antioxidant Status in High-Risk Prostate Cancer Subjects. Diagnostics, 2020, 10, 126.	1.3	38
72	Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed "Sensitive" Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 751-754.	0.5	36

#	Article	IF	Citations
73	Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Investigational New Drugs, 2014, 32, 362-368.	1.2	36
74	Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients. Clinical Cancer Research, 2020, 26, 1915-1923.	3.2	36
75	Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncology Reports, 2012, 27, 286-92.	1.2	35
76	Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer, 2007, 56, 377-381.	0.9	32
77	KMT2D Mutation Is Associated With Poor Prognosis in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e489-e501.	1.1	32
78	A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. EBioMedicine, 2021, 63, 103163.	2.7	32
79	Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy, 2007, 6, 16-25.	0.2	31
80	Humans accumulate microsatellite instability with acquired loss of MLH1 protein in hematopoietic stem and progenitor cells as a function of age. Blood, 2012, 120, 3229-3236.	0.6	31
81	Human β-Defensin 3 Peptide Is Increased and Redistributed in Crohn's Ileitis. Inflammatory Bowel Diseases, 2013, 19, 942-953.	0.9	31
82	Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Science Advances, 2022, 8, .	4.7	31
83	IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice. Biology Direct, 2012, 7, 3.	1.9	29
84	Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study. Lung Cancer, 2020, 142, 90-97.	0.9	29
85	Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. British Journal of Haematology, 2007, 139, 464-474.	1.2	28
86	The Impact of Delayed Chemotherapy on Its Completion and Survival Outcomes in Stage II Colon Cancer Patients. PLoS ONE, 2014, 9, e107993.	1.1	28
87	Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. British Journal of Haematology, 2006, 132, 42-55.	1.2	27
88	Indices to Measure Risk of HIV Acquisition in Rakai, Uganda. PLoS ONE, 2014, 9, e92015.	1.1	27
89	Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Investigational New Drugs, 2014, 32, 729-738.	1.2	27
90	Barriers to Follow-Up Colonoscopy After Positive FIT or Multitarget Stool DNA Testing. Journal of the American Board of Family Medicine, 2021, 34, 61-69.	0.8	27

#	Article	IF	Citations
91	Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2021, 156, 231-238.	0.3	26
92	Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. Npj Breast Cancer, 2021, 7, 104.	2.3	26
93	Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. , 2022, 10, e003778.		26
94	O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemotherapy and Pharmacology, 2007, 60, 415-421.	1.1	25
95	PIAS3 expression in squamous cell lung cancer is low and predicts overall survival. Cancer Medicine, 2015, 4, 325-332.	1.3	25
96	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. JAMA Network Open, 2022, 5, e227722.	2.8	25
97	Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. Brachytherapy, 2007, 6, 149-156.	0.2	24
98	Multi-Institutional Phase I Trials of Anticancer Agents. Journal of Clinical Oncology, 2008, 26, 1926-1931.	0.8	24
99	Characterization of the facial microbiome in twins discordant for rosacea. Experimental Dermatology, 2018, 27, 295-298.	1.4	24
100	T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learningâ€"derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology. European Radiology, 2021, 31, 1336-1346.	2.3	24
101	Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma. Journal of Clinical Investigation, 2021, 131, .	3.9	24
102	CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma. Molecular Cancer Therapeutics, 2015, 14, 740-746.	1.9	23
103	An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients With HPV-Associated Oropharyngeal Cancer. Journal of the National Cancer Institute, 2022, 114, 609-617.	3.0	23
104	Recipient-Specific Tolerance after HLA-Mismatched Umbilical Cord Blood Stem Cell Transplantation. Transplantation, 2005, 80, 1316-1322.	0.5	22
105	Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2009, 147, 89-96.	1.2	22
106	Phase I Clinical Trial of O6-Benzylguanine and Topical Carmustine in the Treatment of Cutaneous T-Cell Lymphoma, Mycosis Fungoides Type. Archives of Dermatology, 2012, 148, 613-20.	1.7	22
107	High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: An effective regimen with low morbidity and mortality. Biology of Blood and Marrow Transplantation, 2005, 11, 13-22.	2.0	21
108	NRP-1/CD304 Expression in Acute Leukemia. American Journal of Clinical Pathology, 2012, 137, 39-50.	0.4	21

#	Article	IF	Citations
109	Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network. Journal of Clinical Immunology, 2019, 39, 448-458.	2.0	21
110	HPV Infection and EGFR Activation/Alteration in HIV-Infected East African Patients with Conjunctival Carcinoma. PLoS ONE, 2010, 5, e10477.	1.1	21
111	Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 216, 82-91.	1.9	20
112	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. Oncologist, 2015, 20, 1298-1303.	1.9	19
113	Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 2839-2849.	0.6	19
114	A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 55-60.	1.3	18
115	Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans. European Journal of Cancer, 2021, 148, 146-158.	1.3	18
116	Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia and Lymphoma, 2007, 48, 1940-1949.	0.6	17
117	Clinical Trial Design in Small Cell Lung Cancer: Surrogate End Points and Statistical Evolution. Clinical Lung Cancer, 2014, 15, 207-212.	1.1	17
118	The Effects of a Single Electronic Music Improvisation Session on the Pain of Adults with Sickle Cell Disease: A Mixed Methods Pilot Study. Journal of Music Therapy, 2018, 55, 156-185.	0.6	17
119	Computer Extracted Features from Initial H&E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance. Cancers, 2020, 12, 2708.	1.7	17
120	Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management. Biology of Blood and Marrow Transplantation, 2013, 19, 1204-1209.	2.0	16
121	Dual institution experience of nodal marginal zone lymphoma reveals excellent long‐term outcomes in the rituximab era. British Journal of Haematology, 2016, 175, 275-280.	1.2	16
122	The use of 3-dimensionally printed models to optimize patient education and alleviate perioperative anxiety in Mohs micrographic surgery: A randomized controlled trial. Journal of the American Academy of Dermatology, 2019, 81, 1339-1345.	0.6	16
123	Radiomic Features Associated With HPV Status on Pretreatment Computed Tomography in Oropharyngeal Squamous Cell Carcinoma Inform Clinical Prognosis. Frontiers in Oncology, 2021, 11, 744250.	1.3	16
124	Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens. Oncology Letters, 2017, 14, 3927-3934.	0.8	15
125	Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. European Urology Focus, 2021, 7, 722-732.	1.6	15
126	Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. Oncotarget, 2017, 8, 79864-79875.	0.8	15

#	Article	IF	Citations
127	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 744724.	1.3	15
128	Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Brachytherapy, 2003, 2, 215-222.	0.2	14
129	Plasmacytoid Dendritic Cells Mediate Synergistic Effects of HIV and Lipopolysaccharide on CD27^{+}IgD$^{–}$Memory B Cell Apoptosis. Journal of Virology, 2014, 88, 11430-11441.	1.5	14
130	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. Radiotherapy and Oncology, 2016, 121, 335-341.	0.3	14
131	Socioeconomic Factors and Survival of Multiple Myeloma Patients. Cancers, 2021, 13, 590.	1.7	14
132	Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Current HIV Research, 2018, 16, 143-150.	0.2	14
133	Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemotherapy and Pharmacology, 2009, 65, 73-78.	1.1	13
134	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. Npj Precision Oncology, 2021, 5, 35.	2.3	13
135	Risk factors for radiation induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy. Annals of Translational Medicine, 2021, 9, 1288-1288.	0.7	13
136	Integrated Clinical and CT Based Artificial Intelligence Nomogram for Predicting Severity and Need for Ventilator Support in COVID-19 Patients: A Multi-Site Study. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 4110-4118.	3.9	13
137	Nuclear Factor-κB/p65 (Rel A) Is Constitutively Activated in Human Prostate Adenocarcinoma and Correlates with Disease Progression. Neoplasia, 2004, 6, 390-400.	2.3	13
138	Cellular Expression of CD23, CD71, and CD38 Are Independent Prognostic Variables in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2801-2801.	0.6	13
139	Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detection and Prevention, 2005, 29, 133-145.	2.1	12
140	Phase II study of erlotinib and docetaxel with concurrent intensity‑modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E1770-6.	0.9	12
141	Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‑term outcomes. British Journal of Haematology, 2016, 173, 404-412.	1.2	12
142	The effects of music therapy on transition outcomes in adolescents and young adults with sickle cell disease. International Journal of Adolescent Medicine and Health, 2019, 31, .	0.6	12
143	Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free Survival. Journal of Clinical Oncology, 2009, 27, 4135-4141.	0.8	11
144	Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. Hematology, 2017, 22, 405-411.	0.7	11

#	Article	IF	Citations
145	A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer. EBioMedicine, 2021, 69, 103481.	2.7	11
146	Peritransplant Use of Ultraviolet-B Irradiation (UV-B) Therapy Is Detrimental to Allogeneic Stem Cell Transplantation Outcome. Biology of Blood and Marrow Transplantation, 2006, 12, 665-671.	2.0	10
147	Maturation of the mucosal immune system underlies colitis susceptibility in interleukin-10-deficient (IL-10â˜’/â˜’) mice. Journal of Leukocyte Biology, 2007, 82, 311-319.	1.5	10
148	Relationship between phase I study duration and symptom burden. Supportive Care in Cancer, 2018, 26, 731-737.	1.0	10
149	Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. Radiotherapy and Oncology, 2021, 162, 26-33.	0.3	10
150	Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities. , 2022, 10, e003833.		10
151	Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Investigational New Drugs, 2005, 23, 563-567.	1.2	9
152	Vancomycin-resistant enterococci infection: not just for the transplanted. Leukemia and Lymphoma, 2014, 55, 1320-1325.	0.6	9
153	Next Generation Sequencing of Advanced Nonâ€"Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. Clinical Lung Cancer, 2021, 22, 16-22.e1.	1.1	9
154	A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials. Cancer Medicine, 2021, 10, 4312-4321.	1.3	9
155	Phase I clinical trials in patientsâ‰¥80. Journal of Geriatric Oncology, 2011, 2, 142-146.	0.5	8
156	Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. Journal of Geriatric Oncology, 2011, 2, 215-221.	0.5	8
157	The functional duality of HoxB4 in hematopoietic reconstituting cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 127-133.	1.1	8
158	A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Investigational New Drugs, 2013, 31, 1244-1250.	1.2	8
159	The Effect of Shift Work and Poor Sleep on Self-Reported Skin Conditions: A Survey of Call Center Agents in the Philippines. Clocks & Sleep, 2019, 1, 273-279.	0.9	8
160	Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma â€• specific venous thrombosis prediction models. American Journal of Hematology, 2020, 95, 918-926.	2.0	8
161	Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation. Translational Lung Cancer Research, 2020, 9, 2315-2327.	1.3	8
162	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. Translational Lung Cancer Research, 2013, 2, 251-5.	1.3	8

#	Article	IF	Citations
163	Is Response Rate Relevant to the Phase II Trial Design of Targeted Agents?. Journal of Clinical Oncology, 2008, 26, 1204-1205.	0.8	7
164	Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1926-1931.	2.0	7
165	Presence of Specific Periodontal Pathogens in Prostate Gland Diagnosed With Chronic Inflammation and Adenocarcinoma. Cureus, 2021, 13, e17742.	0.2	7
166	Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197.. Journal of Clinical Oncology, 2018, 36, 540-540.	0.8	7
167	Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy. Brachytherapy, 2013, 12, 422-427.	0.2	6
168	Evaluation of O6-Benzylguanineâ' Potentiated Topical Carmustine for Mycosis Fungoides. JAMA Dermatology, 2017, 153, 413.	2.0	6
169	Repositioning Fenofibrate to Reactivate p53 and Reprogram the Tumor-Immune Microenvironment in HPV+ Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 282.	1.7	6
170	Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. Clinical Cancer Research, 2022, 28, 4410-4424.	3.2	6
171	Deficient IFN-Â Expression in Umbilical Cord Blood (UCB) T Cells Can Be Rescued by IFN-Â-Mediated Increase in NFATc2 Expression. Journal of Clinical Immunology, 2003, 23, 485-497.	2.0	5
172	Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord Blood Transplant (UCBT) in the Reduced-Intensity Conditioning Setting.. Blood, 2008, 112, 1960-1960.	0.6	5
173	Identification of Key Genes Associated with Progression and Prognosis of Bladder Cancer through Integrated Bioinformatics Analysis. Cancers, 2021, 13, 5931.	1.7	5
174	Effects of pimecrolimus versus triamcinolone on Langerhans cells after UV exposure. Experimental Dermatology, 2011, 20, 280-282.	1.4	4
175	Evaluating the role of phase I expansion cohorts in oncologic drug development. Investigational New Drugs, 2017, 35, 108-114.	1.2	4
176	High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. Lung Cancer, 2018, 126, 48-54.	0.9	4
177	Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. Investigational New Drugs, 2021, 39, 142-151.	1.2	4
178	Peptide Derivatives of Retinylamine Prevent Retinal Degeneration with Minimal Side Effects on Vision in Mice. Bioconjugate Chemistry, 2021, 32, 572-583.	1.8	4
179	Computational pathology reveals unique spatial patterns of immune response in H&E images from COVID-19 autopsies: preliminary findings. Journal of Medical Imaging, 2021, 8, 017501.	0.8	4
180	Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. Cancer Reports, 2021, , e1525.	0.6	4

#	Article	IF	Citations
181	Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses.. Journal of Clinical Oncology, 2013, 31, 8114-8114.	0.8	4
182	Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 1084-1084.	0.6	4
183	Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis.. Journal of Clinical Oncology, 2020, 38, e15099-e15099.	0.8	4
184	Computerâ€extracted features of nuclear morphology in hematoxylin and eosin images distinguish <scp>s</scp>tage <scp>II</scp> and <scp>IV</scp> colon tumors. Journal of Pathology, 2022, 257, 17-28.	2.1	4
185	Comparison of survival times in a transplant study of hematologic disorders. Contemporary Clinical Trials, 2006, 27, 174-182.	0.8	3
186	Americaâ€™s Youngest Kindergartenersâ€™ Elevated Levels of Internalizing Problems at School Entry and Beyond: Evidence from the Early Childhood Longitudinal Study. School Mental Health, 2012, 4, 129-142.	1.1	3
187	Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.. Journal of Clinical Oncology, 2021, 39, 3054-3054.	0.8	3
188	Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).. Journal of Clinical Oncology, 2014, 32, 6070-6070.	0.8	3
189	Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexedâ€"Platinumâ€"Radiation in Patients with Advanced Nonsquamous Nonâ€"Small Cell Lung Cancer: Results of a Phase I Trial. Clinical Cancer Research, 2022, 28, 646-652.	3.2	3
190	Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation. JCO Clinical Cancer Informatics, 2022, 6, e2100156.	1.0	3
191	Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC). Cancers, 2022, 14, 2695.	1.7	3
192	Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1450-1457.	0.6	2
193	1649: Spectict Capromab Pendetide Independently Predicts BDFS in Long Term Outcome Study. Journal of Urology, 2006, 175, 532-532.	0.2	2
194	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. Reviews on Recent Clinical Trials, 2017, 12, 51-58.	0.4	2
195	Association of MLL2 mutation positive non-small cell lung cancer with prognosis.. Journal of Clinical Oncology, 2017, 35, 11598-11598.	0.8	2
196	Early Transplant Improves Outcomes in Patients with Chronic Granulomatous Disease: Results from United States Immunodeficiency Network (USIDNET). Blood, 2017, 130, 671-671.	0.6	2
197	The Prognostic Factors for Early Fatal Outcome in Patients with Multiple Myeloma. Blood, 2019, 134, 270-270.	0.6	2
198	Implementation of a precision medicine thoracic (PREDICT) service using reflex testing in a large academic-community practice network.. Journal of Clinical Oncology, 2022, 40, 6572-6572.	0.8	2

#	Article	IF	Citations
199	Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer. , 2015, 3, .		1
200	Survival in men older than 75 years with low- and intermediate-grade prostate cancer managed with watchful waiting with active surveillance. Family Medicine and Community Health, 2015, 3, 25-36.	0.6	1
201	Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 314-319.	0.7	1
202	Serâ€486/491 phosphorylation and inhibition of AMPKÎ± activity is positively associated with Gleason score, metastasis, and castrationâ€resistance in prostate cancer: A retrospective clinical study. Prostate, 2018, 78, 714-723.	1.2	1
203	Lymphopenia as a predictor of survival in chemoradiation-treated stage III non-small-cell lung cancer (NSCLC): a multi-center retrospective analysis. Journal of Radiation Oncology, 2019, 8, 163-170.	0.7	1
204	Risk of Progression Across Age and Race for Patients with Smoldering Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e325.	0.2	1
205	â€œSecondary MGUSâ€•After High-Dose Melphalan and Autologous Hematopoietic Progenitor Cell Transplantation In Multiple Myeloma: A Matter of Undetermined Significance.. Blood, 2010, 116, 1296-1296.	0.6	1
206	Identification of RICTOR amplification as a recurrent and potentially actionable alteration in small cell lung cancer patients.. Journal of Clinical Oncology, 2015, 33, 7576-7576.	0.8	1
207	Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia. Blood, 2018, 132, 1404-1404.	0.6	1
208	Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients. Blood, 2019, 134, 424-424.	0.6	1
209	Prognostic Value of Dynamic Monoclonal Protein Pattern on Probability of Myeloma Progression from the Precursor State. Blood, 2021, 138, 3781-3781.	0.6	1
210	Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs. Blood, 2020, 136, 19-20.	0.6	1
211	Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer. Frontiers in Oncology, 2022, 12, 811794.	1.3	1
212	Racial disparity in survival of African-American (AA) patients diagnosed with metastatic prostate cancer: Analysis of surveillance epidemiology and end results program.. Journal of Clinical Oncology, 2022, 40, 28-28.	0.8	1
213	Temporal evolution of patient characteristics enrolled on phase I trials. Investigational New Drugs, 2011, 29, 312-315.	1.2	0
214	Early Response to Initial Induction Chemotherapy in Acute Myeloid Leukemia (AML) and Outcomes after Allogeneic Hematopoietic Cell Transplant (HCT). Biology of Blood and Marrow Transplantation, 2015, 21, S194.	2.0	0
215	Outcomes and healthcare utilization in children and young adults with aplastic anemia: A multiinstitutional analysis. Pediatric Blood and Cancer, 2017, 64, e26704.	0.8	0
216	Role of Cdk5 in Acute Graft Versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplant: Correlation with Diagnosis and Severity, Prediction of Survival. Biology of Blood and Marrow Transplantation, 2018, 24, S179-S180.	2.0	0

#	Article	IF	Citations
217	History of drug use in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2021, 56, 581-585.	1.3	0
218	Racial differences in incidence, outcomes, and genomic alterations in small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 8514-8514.	0.8	0
219	In Vitro Characteristics of Umbilical Cord Blood Derived Mononuclear Cells, CD133+ Cells and Endothelial Generating Cells and Their Effectiveness In Vivo in Mediating Neovascularization in a Murine Model of Hind-Limb Ischemia.. Blood, 2004, 104, 3922-3922.	0.6	0
220	Time-Dependent Effect of Non-Hodgkin’s Lymphoma Grade on Disease Free Survival (DSF) of Relapsed/Refractory Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Hematopoietic Stem Cell Transplant (AHSCT).. Blood, 2004, 104, 917-917.	0.6	0
221	Augmentation of Vasculogenesis by Injected Human Hematopoietic Stem Cells in Response to Ischemia Follows Early Activation of Innate Immune Response.. Blood, 2007, 110, 4051-4051.	0.6	0
222	Augmentation of Murine Vasculogenesis by Injected Human Hematopoietic Stem Cells in Response to Ischemia Follows Early Activation of Innate Immune Response. Blood, 2008, 112, 4738-4738.	0.6	0
223	Charlson Comorbidity Index (CCI) Not Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Successfully Predicts Transplant Related Mortality and Post-Transplant Outcomes in Elderly Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. Blood, 2011, 118, 3006-3006.	0.6	0
224	BEP Versus BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Relapsed Lymphoma. A Single Center Retrospective Review of Two Contemporaneous Cohorts. Blood, 2011, 118, 2019-2019.	0.6	0
225	Clinical trial design in small cell lung cancer: Surrogate endpoints and statistical evolution.. Journal of Clinical Oncology, 2012, 30, 7087-7087.	0.8	0
226	Docetaxel, carboplatin, trastuzumab, and bevacizumab (TCH+B) for early-stage HER2/neu(+) breast cancer and bone marrow micrometastases.. Journal of Clinical Oncology, 2012, 30, TPS655-TPS655.	0.8	0
227	Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT. Blood, 2013, 122, 2117-2117.	0.6	0
228	Fingolimod Expands Human Umbilical Cord Blood Cells (UCB) in Vitro and Improves Engraftment Rate of Human UCB in Sublethally Irradiated NOD SCID Gamma (NSG) Mice. Blood, 2014, 124, 2413-2413.	0.6	0
229	Retinoblastoma mutation to predict poor outcomes in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9060-9060.	0.8	0
230	Development of a prognostic risk model for small cell lung cancer: Identification of high-, intermediate-, and low-risk cohorts based on clinical-genomic data.. Journal of Clinical Oncology, 2019, 37, 8554-8554.	0.8	0
231	Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2019, 134, 5646-5646.	0.6	0
232	Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay. Blood, 2019, 134, 2607-2607.	0.6	0
233	Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction. Blood, 2019, 134, 4770-4770.	0.6	0
234	Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.. Journal of Clinical Oncology, 2020, 38, 4623-4623.	0.8	0

#	Article	IF	Citations
235	A highly effective and practical desensitization regimen: Results in comparable clinical outcomes for multiple myeloma patients with skin rash after immunomodulatory drugs.. Journal of Clinical Oncology, 2020, 38, 12104-12104.	0.8	0
236	Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial.. Journal of Clinical Oncology, 2020, 38, 9027-9027.	0.8	0
237	Temporal Pattern of Co-Development of Internalizing and Externalizing Problem Behaviors: An Application of Bivariate Mixed-Effects Models. Reviews on Recent Clinical Trials, 2020, 15, 60-69.	0.4	0
238	Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients. Blood, 2021, 138, 2536-2536.	0.6	0
239	Towards CD177 As a Predictive Biomarker for Hypomethylating Agent Response in Myelodysplastic Syndrome. Blood, 2021, 138, 4665-4665.	0.6	0
240	A Longitudinal Evaluation of Cytopenia Severity in Patients with Clonal Cytopenia of Undetermined Significance (CCUS) and Correlation with the Presence of Sub-Clinical Dysplasia. Blood, 2021, 138, 3705-3705.	0.6	0
241	Computer extracted features of tumor-infiltrating lymphocytes (TILs) architecture are prognostic of progression-free survival in stage III colon cancer. , 2022, , .		0
242	Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng<i>et al</i>. , 2022, 10, e005086.		0
243	Survival in patients with prostate cancer and history of autoimmune disease.. Journal of Clinical Oncology, 2022, 40, e17001-e17001.	0.8	0
244	Survival in patients with breast cancer and history of autoimmune disease.. Journal of Clinical Oncology, 2022, 40, 1020-1020.	0.8	0